Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Irmgard Nippert has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Role of Patient Organizations in Shaping Research, Health Policies, and Health Services for Rare Genetic Diseases: The Dutch Experience

    by Ysbrand Poortman, Martina Ens-Dokkum, Irmgard Nippert

    In 2023, the genetics scientific community celebrated two special anniversaries: the discovery of the double helix structure of DNA was published in 1953 and in 2003 the Human Genome Project was declared completed and made publicly available. To this day, genetics and genomics research is continuing to evolve at high pace and is identifying a steadily increasing number of genes as causal for distinct genetic diseases. The success story of genetics and genomics would not be complete without taking due account of the role of patient advocacy organizations in this process. This paper is based on the personal narrative (oral history) of a father whose daughter was born with a rare genetic disease (RGD) in the 1960s. The first-hand experience of living as a family with an RGD in those days made him a leading pioneer not only in the foundation of patient organizations at national, pan-European, and international levels but also in the development of multi-stakeholder co-operation and networking. Today, patient advocacy organizations play an active role in shaping health and research policies at national, EU, and international levels to ensure that their needs in regard to advancing RGD diagnostics, care, and treatment are addressed.


  • Open Access

    Life situation of women impaired by Thalidomide embryopathy in North Rhine-Westphalia - a comparative analysis of a recent cross-sectional study with earlier data

    by Christina Samel, Christian Albus, Irmgard Nippert, Alexander Niecke, Markus Lüngen, Holger Pfaff, Klaus M. Peters

    Between 1957 and 1961 the substance Thalidomide was sold in West Germany and taken by many women as a sedative during pregnancy. This lead to miscarriages and infants been born with several severe malformations. The aim of this study was to describe the current situation of women impaired by Thalidomide induced embryopahty in North Rhine-Westphalia (Nordrhein-Westfalen), Germany, in comparison with the results found in a study done in 2002 by Nippert et al. Questionnaires as well as examinations were performed. Data were compared using descriptive and inductive statistical methods. Both studies show that women impaired by Thalidomide embryopathy face a poorer health status than women their age in the general population and live in fear of further deteriorating health. The majority can only work reduced hours or are already retired due to poor health. Most of those who need assistance are being assisted by their social environment, while professional care is still utilized in only few cases. An obvious need for a shift in the provision of assistance and/or care provided was found as the social environment supporting the impaired women is also aging and therefore in high danger of breaking apart. The study has been registered at German Clinical Trials Register, DRKS00010593 , on 07.06.2016 retrospectively.


  • Breast surgeons' attitudes towards bilateral risk-reducing mastectomy: A National Survey of American Surgeons.

    by Narendra Nath Basu, Mariska Den Heijer, Christi J van Asperen, Hilary Harris, Irmgard Nippert, Joerg Schmidtke, Anne Deborah Bouhnik, Claire Julian-Reynier, Peter D. Beitsch, Aad Tibben, et al.

    25 Background: Bilateral risk-reducing mastectomy (BRRM) confers the greatest risk-reduction in women at high-risk of developing breast cancer. Uptake of BRRM is influenced by the attitudes of these women as well as the breast surgeons offering these procedures. We surveyed surgeon members of the American Society of Breast Surgeons to assess their attitudes and knowledge. Methods: An International Cancer Risk Communication Study (InCRisC) questionnaire, previously used to assess attitudes of European physicians and surgeons was sent to 2648 members. Personal and occupational characteristics were recorded and knowledge of cancer genetics and attitudes to BRRM were assessed using clinical vignettes. Results: 439 breast surgeons responded. 98% of surgeons actively took a family history of the father. Almost 100% of surgeons reported a positive attitude towards BRRM. Female surgeons and those treating greater than 100 breast cancers a year were predictors of knowledge of breast cancer genetics and a positive attitude towards BRRM. Conclusions: Multiple factors contribute to surgeons' attitudes towards BRRM. Gender of surgeon and workload contribute to theses observed variations.

  • Cancer risk communication, predictive testing and management in France, Germany, the Netherlands and the UK: general practitioners' and breast surgeons' current practice and preferred practice responsibilities

    by Irmgard Nippert, Claire Julian-Reynier, Hilary Harris, Gareth Evans, Christi J. van Asperen, Aad Tibben, Jörg Schmidtke

    Genetic testing has its greatest public health value when it identifies individuals who will benefit from specific interventions based upon their risk. This paradigm is the basis for the use of predictive tests, such as BRCA1/BRCA2 testing which has become part of clinical practice for more than a decade. Currently predictive BRCA1/BRCA2 testing is offered to women using low, moderate and high risk based upon family history as cut-off levels. Non-genetic health professionals such as general practitioners (GPs) and breast surgeons (BS) are seen as gatekeepers to manage demand and/or facilitate access to appropriate services for high-risk patients. Data about current practices are lacking. The paper presents data on the current practice of GPs' and BS' cancer risk assessment, referral practices and preferred practice responsibilities for women at risk for familial breast cancer in France, Germany, the Netherlands and the UK derived by a self-administered questionnaire send to a representative sample of GPs and BS in the four countries. One thousand one hundred ninety-seven GPs and 1,223 BS completed the questionnaire. Both GPs and BS reported that they are consulted by a considerable number of patients presenting with concerns about a family history of cancer. Both commonalities and striking differences could be observed between GPs and BS from the four participating countries. GPs from France and Germany reported significantly higher proportions taking a family history of cancer including the extended family than GPs from the Netherlands and the UK. Most GPs from France, Germany and the Netherlands stated their willingness for providing risk assessment for an unaffected (high-risk) woman with a family history of breast cancer and the vast majority of BS from all four countries reported that they themselves would provide risk assessment for an unaffected (high-risk) woman with a family history of breast cancer. However, a substantial number of both GPs and BS would not have taken an appropriate family history for their patient failing to take into account the paternal side of the family. GPs from Germany reported a significantly lower readiness to refer a patient with a family history of a BRCA1 mutation for specialist genetic counselling when compared to the GPs from the other countries. GPs and BS from France, Germany and the Netherlands significantly less often assigned practice responsibilities to a genetic specialist as compared to the participating GPs and BS from the UK. The outcome of the study confirms the need for capability building in genetics for non-genetic health professionals. Using genetic risk assessment tools without a full understanding could result in missed opportunities for cancer prevention and harm patients. In order to provide best possible services for high-risk patients presenting with cancer concerns, close collaboration with clinical geneticists should become routine part of mainstream medical practice.


  • Confidence of primary care physicians in their ability to carry out basic medical genetic tasks—a European survey in five countries—Part 1

    by Irmgard Nippert, Hilary J. Harris, Claire Julian-Reynier, Ulf Kristoffersson, Leo P. Ten Kate, Elizabeth Anionwu, Caroline Benjamin, Kirsty Challen, Jörg Schmidtke, R. Peter Nippert, et al.

    Western health care systems are facing today increasing movement of genetic knowledge from research labs into clinical practice. This paper reports the results of a survey that addressed the confidence of primary care physicians in their ability to carry out basic medical genetic tasks. The survey was conducted in five countries (France, Germany, The Netherlands, Sweden and the UK). Stratified random samples were drawn from primary care physicians in the five countries representing a sampling frame of 139,579 physicians. Stepwise binary logistic regression procedures were performed to identify the predictor variables for self-reported confidence. Three thousand six hundred eighty-six physicians participated and filled out a self-administered questionnaire. The margin of error for accurate representation of each group of European general practitioners and specialists in the total sample is 2.9% for GP, 2.8% for obstetricians/gynaecologists (OB/GYN) and for paediatricians (PAED) 2.6% (95% confidence level). Confidence in their ability to carry out basic medical genetic tasks is low among participating primary care physicians: 44.2% are not confident, 36.5% somewhat confident, confident or very confident are 19.3%. In each country, those confident/very confident represent less than 33% of the participating physicians. Primary care physicians who report the lowest levels of confidence prove to be those least exposed to medical genetics information and training. Although there are significant differences in the way in which professional education is organised and practice is regulated across European countries, there is a need for a coordinated European effort to improve primary care physicians’ background in medical genetics.


  • Open Access

    General practitioner management of genetic aspects of a cardiac disease: a scenario-based study to anticipate providers’ practices

    by Kirsty Challen, Hilary Harris, Ulf Kristoffersson, Irmgard Nippert, Joerg Schmidtke, Leo P. Ten Kate, Caroline Benjamin, Elizabeth Anionwu, Anne-Marie Plass, Claire Julian-Reynier, et al.

    It is increasingly recognised that genetics will have to be integrated into all parts of primary health care. Previous research has demonstrated that involvement and confidence in genetics varies amongst primary care providers. We aimed to analyse perceptions of primary care providers regarding responsibility for genetic tasks and factors affecting those perceptions. Postal questionnaire including a hypothetical case management scenario of a cardiac condition with a genetic component was sent to random samples of medically qualified general practitioners in France, Germany, Netherlands, Sweden and UK (n = 1,168). Logistic regression analysis of factors affecting primary care practitioners’ willingness to carry out genetic tasks themselves was conducted; 61% would take a family history themselves but only 38% would explain an inheritance pattern and 16% would order a genetic test. In multivariate analysis, only the country of practice was consistently predictive of willingness to carry out genetic tasks, although male gender predicted willingness to carry out the majority of tasks studied. The stage of career at which education in genetics had been provided was not predictive of willingness to carry out any of the tasks analysed. Country of practice is significantly predictive of attitudes towards genetics in primary care practice and therefore genetic education structure and content in Europe will need to be significantly tailored towards country-specific approaches.


  • Ethische und soziale Aspekte der Pränataldiagnostik: Überblick und Ergebnisse aus interdisziplinären empirischen Untersuchungen

    by Heidemarie Neitzel, Irmgard Nippert

    Since its introduction into maternal health care more than 30 years ago, prenatal diagnosis (PND) is being debated controversially in Germany. The main ethical dilemma associated with PND is the option of selective termination of an affected pregnancy. Another point of concern is PND being presented as a "routine" procedure making it difficult for women to refuse it. When PND was introduced three decades ago there was unanimous agreement that PND should be embedded in pre- and post-test counselling, that PND should only be done with informed consent and that informed consent can only be given if accurate non-biased counselling is provided in a non-directive manner. However, today only a minority of women undergo qualified pre-test (13%) and post-test counselling (18%). Utilization rates of pre- and post-test counselling services are influenced by PND centres and practices and vast regional differences can be observed. Decisions regarding termination of pregnancy depend on many factors including the severity and prognosis of a condition, gestational age and the way in which information about the condition is communicated. In conclusion the uneven availability and accessibility of quality counselling services may impact the wellbeing of women undergoing PND.


  • Women’s Experiences of Undergoing BRCA1 and BRCA2 Testing: Organisation of the German Hereditary Breast and Ovarian Cancer Consortium Survey and Preliminary Data from Münster

    by Irmgard Nippert, Brigitte Schlegelberger

    Background: In order to promote safe and effective testing for BRCA1 and BRCA2 mutations in clinical practice, a network of expert centres in hereditary breast and ovarian cancer (‘Verbundprojekt familiärer Brust- und Eierstockkrebs’; German Consortium on Hereditary Breast and Ovarian Cancer) has been established by the Deutsche Krebshilfe (German Cancer Aid). To improve practice, evaluations based upon the views of patients who have undergone testing concerning the impact of the genetic diagnosis and the quality of the services they receive and require are undertaken. Methods: Herein, we first describe the protocols for interdisciplinary pre- and post-test counselling and for molecular diagnostics, then the feedback from the patients undergoing testing. Women and men who had obtained their test results at least 6 months earlier were interviewed using a questionnaire including open and standardised questions at 11 participating centres in 2002–2003. Reported here are the survey protocol and preliminary data from interviews with women conducted by the centre based at the University of Münster’s Medical School in 2002 (n = 46). Results: Compared to international guidelines, the Consortium’s protocols provide more specifically outlined indications based on the mutation frequencies observed in the German population for families that should be offered interdisciplinary counselling and genetic testing. The data from the Münster survey suggest that there is little regret regarding the decision to undergo testing and that the vast majority of women would undergo the test again. However, women with positive findings experienced more problems than women with negative results. They were less prone to recommend the test and to communicate the tests results in their family compared to women with negative test results. Communication of test results within the family was characterised by preferential information of female family members. Conclusion: BRCA1/2 testing should be provided within a framework that ensures harmonisation and standardisation of services and that protects users. Women and men with positive test results may need special support from counsellors on how to handle test results in their families. Strategies need to be developed and evaluated on how to help stimulate and facilitate the dissemination of information within families without potentially ‘overstraining’ the ‘messenger patient’, at least when a mutation has been identified.


  • 40 Years Later: The Health Related Quality of Life of Women Affected by Thalidomide

    by Irmgard Nippert, Birgit Edler, Claudia Schmidt-Herterich

    Objectives: 40 years ago, the sudden increase of births of babies with a range of severe deformities shocked the world. It was caused by the tranquilizer thalidomide. Women who took the drug in the first trimester of pregnancy gave birth to children with a wide but distinctive range of malformations. Thalidomide claimed more than 10,000 victims worldwide. Those who survived are now reaching middle age. Especially women affected by thalidomide may be at special disadvantage because of combined discrimination based on gender and disability. So far, no study has been published that has investigated their quality of life in health and in health care. Methods: A questionnaire using the WHO QOL-BREF instrument for measuring health-related quality of life was distributed among 166 females impaired by thalidomide. A randomized control group matched by age, sex and area of residence filled out a corresponding questionnaire. Results: Women impaired by thalidomide reported significantly lower quality of life in health and health care as compared to their control group. Over a third reported steadily deteriorating conditions, and a statistically significant higher proportion as compared to the controls has already retired from the workforce. They were significantly less frequently married, had fewer children, had less household incomes and were less mobile. However, women impaired by thalidomide are more likely to be satisfied with their safety in daily life, with their physical environment, with their living conditions and with the support they get from their friends. Conclusions: Although there is increasing clinical research on how to use thalidomide as a drug in new therapies, the specific health needs of women impaired by thalidomide are at risk of being neglected.